MedPath

The trial to evaluate the safety and efficacy of high dose ambroxol in combination with enzyme replacement therapy in Gaucher disease patients

Not Applicable
Recruiting
Conditions
Endocrine, nutritional and metabolic disease
Registration Number
KCT0003218
Lead Sponsor
Asan Medical Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
10
Inclusion Criteria

1) Male and female subjects aged between 2 and 60 years old, inclusive
2) Patients diagnosed with Gaucher disease by genetic testing or enzyme activity assay
3) Voluntarily signed written informed consent by patients or by both patients and their representatives

Exclusion Criteria

1) Patients with severe renal impairment (eGFR < 30 mL/min/1.73 m2)
2) Patients with severe hepatic impairment (Child-Pugh class C)
3) Patients with genetic predisposition to lactose intolerance, galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
4) Patients with known active hepatitis, HIV positive, or other uncontrolled infectious diseases
5) Patients who are unable to orally administer the study drug
6) Patients with hypersensitivities to the study drug or any of its components
7) Pregnant and lactating women, men and women of childbearing potential who are not willing to practice abstinence or use appropriate methods of contraception during the study
8) Patients who participated in any clinical trials other than GD-AMBX-01 within 90 days from treatment with the investigational product
9) Patients who are unable to participate in the study for other reasons, according to the investigator

Study & Design

Study Type
Interventional Study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Adverse events (AEs) (Renal dysfunction, hepatic disease, digestive disorder, allergy and anaphylactoid reaction, Stevens-Johnson syndrome, Lyell syndrome, purulent rhinitis, etc.);Laboratory tests (hematology, blood chemistry, blood coagulation, and urinalysis);Vital signs (blood pressure, pulse, body temperature) and body measurements (body mass index);Electrocardiogram (ECG) and chest X-ray
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath